Wall Street analysts predict that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) will announce $2.05 billion in sales for the current quarter, Zacks reports. Six analysts have made estimates for Valeant Pharmaceuticals Intl’s earnings. The highest sales estimate is $2.11 billion and the lowest is $2.01 billion. Valeant Pharmaceuticals Intl reported sales of $2.23 billion in the same quarter last year, which indicates a negative year over year growth rate of 8.1%. The business is scheduled to issue its next quarterly earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Valeant Pharmaceuticals Intl will report full year sales of $8.29 billion for the current financial year, with estimates ranging from $8.16 billion to $8.41 billion. For the next year, analysts expect that the business will report sales of $8.41 billion per share, with estimates ranging from $8.05 billion to $8.81 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Valeant Pharmaceuticals Intl.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.29. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.95 billion. During the same period in the previous year, the company posted $1.79 EPS. The company’s quarterly revenue was down 5.4% compared to the same quarter last year.
Several equities analysts have weighed in on VRX shares. JPMorgan Chase & Co. set a $13.00 price objective on shares of Valeant Pharmaceuticals Intl and gave the stock a “sell” rating in a research report on Wednesday, May 9th. TD Securities lowered their price objective on shares of Valeant Pharmaceuticals Intl from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, March 1st. Wells Fargo & Co reiterated a “sell” rating on shares of Valeant Pharmaceuticals Intl in a research report on Wednesday, February 28th. TheStreet cut shares of Valeant Pharmaceuticals Intl from a “c” rating to a “d+” rating in a research report on Friday, May 25th. Finally, Cantor Fitzgerald set a $25.00 price target on shares of Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a report on Wednesday, February 28th. Five investment analysts have rated the stock with a sell rating, eleven have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Valeant Pharmaceuticals Intl currently has a consensus rating of “Hold” and an average target price of $20.54.
NYSE VRX traded down $0.45 on Monday, hitting $24.27. 6,174,842 shares of the stock were exchanged, compared to its average volume of 8,742,270. Valeant Pharmaceuticals Intl has a 52-week low of $10.94 and a 52-week high of $27.79. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18. The stock has a market cap of $8.63 billion, a price-to-earnings ratio of 6.34, a PEG ratio of 0.37 and a beta of -0.34.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was purchased at an average cost of $21.83 per share, for a total transaction of $327,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.87% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Rational Advisors LLC bought a new stake in Valeant Pharmaceuticals Intl in the first quarter worth $1,312,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its holdings in Valeant Pharmaceuticals Intl by 1,533.2% in the first quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 501,400 shares of the specialty pharmaceutical company’s stock worth $10,284,000 after purchasing an additional 470,700 shares in the last quarter. Tuttle Tactical Management acquired a new position in Valeant Pharmaceuticals Intl during the 1st quarter worth $1,312,000. Alpine Global Management LLC lifted its position in Valeant Pharmaceuticals Intl by 24.6% during the 1st quarter. Alpine Global Management LLC now owns 41,750 shares of the specialty pharmaceutical company’s stock worth $665,000 after acquiring an additional 8,250 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Valeant Pharmaceuticals Intl by 16.9% during the 1st quarter. Millennium Management LLC now owns 496,313 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after acquiring an additional 71,900 shares during the last quarter. Hedge funds and other institutional investors own 46.95% of the company’s stock.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.
Get a free copy of the Zacks research report on Valeant Pharmaceuticals Intl (VRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.